MONTE ROSA THERAPEUTICS INC
NASDAQ: GLUE (Monte Rosa Therapeutics, Inc.)
Last update: 5 hours ago17.75
-0.75 (-4.05%)
| Previous Close | 18.50 |
| Open | 18.08 |
| Volume | 1,831,015 |
| Avg. Volume (3M) | 1,583,939 |
| Market Cap | 1,353,308,928 |
| Price / Earnings (TTM) | 55.47 |
| Price / Sales | 3.54 |
| Price / Book | 1.76 |
| 52 Weeks Range | |
| Earnings Date | 19 Mar 2026 |
| Profit Margin | 3.86% |
| Operating Margin (TTM) | 51.85% |
| Diluted EPS (TTM) | 0.120 |
| Quarterly Revenue Growth (YOY) | 7,882.00% |
| Total Debt/Equity (MRQ) | 15.21% |
| Current Ratio (MRQ) | 5.61 |
| Operating Cash Flow (TTM) | 34.67 M |
| Levered Free Cash Flow (TTM) | 40.54 M |
| Return on Assets (TTM) | -0.40% |
| Return on Equity (TTM) | 2.88% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Monte Rosa Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -1.5 |
| Price Volatility | -3.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.73% |
| % Held by Institutions | 101.33% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Nea Management Company, Llc | 31 Dec 2025 | 7,692,298 |
| Versant Venture Management, Llc | 31 Dec 2025 | 4,382,687 |
| Aisling Capital Management Lp | 31 Dec 2025 | 1,472,331 |
| Mpm Bioimpact Llc | 31 Dec 2025 | 1,173,376 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 37.00 (Piper Sandler, 108.45%) | Buy |
| Median | 34.00 (91.55%) | |
| Low | 30.00 (Wells Fargo, 69.01%) | Buy |
| Average | 33.67 (89.69%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 24.89 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Piper Sandler | 14 Jan 2026 | 37.00 (108.45%) | Buy | 24.06 |
| Guggenheim | 08 Jan 2026 | 34.00 (91.55%) | Buy | 25.31 |
| Wells Fargo | 08 Jan 2026 | 30.00 (69.01%) | Buy | 25.31 |
| 16 Dec 2025 | 22.00 (23.94%) | Buy | 18.66 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| JANKU FILIP | - | 19.51 | -9,189 | -179,277 |
| Aggregate Net Quantity | -9,189 | |||
| Aggregate Net Value ($) | -179,277 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 19.51 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| JANKU FILIP | Officer | 23 Feb 2026 | Sell (-) | 9,189 | 19.51 | 179,277 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |